Protein kinase inhibitors to treat non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Protein kinase inhibitors to treat non-small-cell lung cancer.

Protein kinase inhibitors to treat non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38205518

about

Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.Neuroblastoma: molecular pathogenesis and therapy.Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.Emerging paradigms in targeted treatments for Asian patients with NSCLC.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

P2860

Q26851417-B6D2CEC0-A983-4C26-9EAE-2962C53ACB2A Q28082487-5B52941B-8711-4E4E-96F5-CF834255D832 Q35068234-A28F57BE-0053-4872-AA41-1178BACDC36C Q35484306-4D315383-8A9F-4F82-B527-A679B0E4562C Q35564199-AEFC15A3-3AA8-4394-968C-E4D676721343 Q35740066-69C0AC4B-684C-4C29-90A7-1C81393F0E24 Q37564535-511102C3-A7A4-49DC-A51F-11EA84150B59 Q38439446-0C093686-8238-4DDE-A995-17DF115FAA5E Q38969204-4B3226A0-E2E1-46DF-AC11-B823E49FFBEA Q41587809-0C2A35DC-31E2-42B0-9874-C2AFD86903D9 Q42697768-5EAD0308-1FF3-405D-AACA-020ECF6AE98C Q52921226-3046E529-8D3A-44DC-8F69-72D651451DDF

P2860

Protein kinase inhibitors to treat non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38205518

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Protein kinase inhibitors to treat non-small-cell lung cancer.

@en

type

label

Protein kinase inhibitors to treat non-small-cell lung cancer.

@en

prefLabel

Protein kinase inhibitors to treat non-small-cell lung cancer.

@en

P1433

Q38205518-E6EA8F17-1A5C-4260-821F-CEB78019AB41

P1476

Q38205518-2BC418F6-32EA-49CA-86DA-08680FFD5F52

P2093

Q38205518-6D0CA9F2-F0FC-46A4-B1D1-5EE0A21EDFCB

Q38205518-9BD38AD4-2CF2-4573-9E3C-24B3C39A1CFF

Q38205518-E159C94E-8515-421D-B1FA-538F29D4E918

P2860

Q38205518-08F5E0B4-B57B-47C9-8839-88C8C6DB5AA6

Q38205518-0AAFADF9-AB82-4906-906A-A53BAB7A0EDC

Q38205518-0FF55D7F-B1FB-48DB-8F09-14C3C3AB4419

Q38205518-121A4A62-328E-44F3-BB6F-4068A5D5B24C

Q38205518-133AD798-CE60-4260-A7F6-E0410DAF1A7B

Q38205518-13E60A13-D421-4223-A6B8-30BF777F9958

Q38205518-16EF084C-EE46-4883-BB3D-4E750E3EFDAE

Q38205518-170C1D87-9CF5-4CA1-A06E-90B410751E11

Q38205518-1B834E14-8CBF-4757-A277-5727505D8E5F

Q38205518-1C0AADF9-77C0-4D37-A496-02387C961AFC

P304

Q38205518-0F3B636E-0CEE-4191-A2F9-9CFFD6F2DCE1

P31

Q38205518-4959D9C4-F3EF-4729-925F-B1E48239D955

P356

Q38205518-FD02ACE0-D138-49DA-B354-314137FCD12D

P407

Q38205518-42543B32-C1B8-4E4A-B9D5-0DACE071F934

P433

Q38205518-FF86BADB-58BE-4693-BAA3-D7B36D6F4312

P478

Q38205518-1C0C7B85-CCCF-4CDB-BFA2-F2D146837C7F

P50

Q38205518-DA241DDE-214B-45CA-9E58-A1F9B717FDA6

P577

Q38205518-CF32238E-C762-41DD-9468-CC8ACA03AA12

P698

Q38205518-AC31E9BF-E905-4945-9417-AFAE39DB6AF0

P356

14656566.2014.909412

P1433

Expert Opinion on Pharmacotherapy

P1476

Protein kinase inhibitors to treat non-small-cell lung cancer.

@en

P2093

Armida D'Incecco

http://www.w3.org/2001/XMLSchema#string

Gabriele Minuti

http://www.w3.org/2001/XMLSchema#string

Lorenza Landi

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Somatic mutations affect key pathways in lung adenocarcinoma

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

1203-1213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2014.909412

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Federico Cappuzzo

P577

2014-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24745764

http://www.w3.org/2001/XMLSchema#string